PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

M&A boutique Locust Walk Partners targets life science clients

Locust Walk Partners has been established as a boutique strategic and transaction advisory firm with offices in Boston and Philadelphia, providing strategic reviews and business and cor

Locust Walk Partners has been established as a boutique strategic and transaction advisory firm with offices in Boston and Philadelphia, providing strategic reviews and business and corporate development execution for biopharmaceutical, medical device and diagnostics companies.

Headed by co-founding managing directors Geoff Meyerson and Jay Mohr, the Locust Walk team has a deal track record including buy- and sell-side licensing, mergers and acquisitions, and private and public fundraising.

Team members and advisers have business and corporate development capabilities and operating, scientific, regulatory, intellectual property, and technology transfer competencies.

‘Locust Walk Partners fills a void in the market, providing services not offered by management consulting firms or investment banks,’ Mohr says. ‘Companies need to determine the role of pipeline assets, position them appropriately in the marketplace, and execute a transaction yielding significant value.’

Adds Meyerson: ‘In today’s financial climate, companies want access to strategic advice and business and corporate development expertise in a capital efficient, success driven manner.’

Meyerson has significant transaction experience from roles in investment banking, venture capital, and business development. He has worked for UBS Investment Bank, SROne, MedImmune, and Zelos Therapeutics.

Mohr has nearly 20 years of commercial, operating, business development and company formation/fundraising experience in emerging and established biopharmaceutical companies. He has held senior management positions at Schering-Plough and Serono and other roles at Variagenics/Nuvelo, Gloucester Pharmaceuticals and Zelos.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured